Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;21(4):197-210.
doi: 10.1038/s41584-025-01228-7. Epub 2025 Mar 11.

Hyperuricaemia and gout in the Pacific

Affiliations
Review

Hyperuricaemia and gout in the Pacific

Baptiste Gérard et al. Nat Rev Rheumatol. 2025 Apr.

Abstract

Gout is the most common form of inflammatory arthritis in adults worldwide. There has been a steady increase in prevalence, which varies across different geographic areas and is high in the Indigenous (First Nations) peoples of the Pacific region. Palaeo-archaeological studies demonstrate that gout was present in the Pacific region prior to European colonization, which is suggestive of genetic predisposition. Genetic risk factors, including population-specific genetic variants and genetic variants shared across populations, particularly those influencing urate transporters, have been identified in Indigenous peoples of the Pacific that partly explain the earlier age of onset of gout. Indigenous peoples of the Pacific experience severe gout, with frequent flares, high hospitalization rates and tophaceous gout, all aggravated by socio-cultural factors. Despite a specific need for effective gout management, Indigenous peoples of the Pacific are under-represented in gout research and inequities in care continue. Indigenous peoples-led, holistic gout management programmes are systematically and urgently required in this region, where gout is a major public health issue. Importantly, a foundation of cultural safety is necessary to underpin such programmes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: N.D. has received consulting fees, speaker fees or grants from Aristea, Arthrosi, AstraZeneca, Avalo, Biomarin, Dexcel Pharma, Hikma, Horizon, JPI, JW Pharmaceutical Corporation, LG Chem, Novartis, PK Med, Protalix, PTC Therapeutics, Selecta, Shanton Pharma, Sobi and Unlocked Labs. T.R.M. has received research funding and consulting fees from Variant Bio. L.K.S. has received research funding from the New Zealand Health Research Council and consulting fees from Pharmac outside the submitted work. T.P. has received research funding from Variant Bio and honorary and consulting fees from Horizon Pharmaceuticals and Novartis, unrelated to this work. B.G., M.L., T.B., L.T.K., S.O., S.V., A.L. and E.O. declare no competing interests.

References

    1. Dehlin, M., Jacobsson, L. & Roddy, E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 16, 380–390 (2020). - PubMed - DOI
    1. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 6, e507–e517 (2024). - DOI
    1. Dalbeth, N., Gosling, A. L., Gaffo, A. & Abhishek, A. Gout. Lancet 397, 1843–1855 (2021). - PubMed - DOI
    1. Stamp, L. K., Christensen, R. & Morillon, M. B. Serum urate as a surrogate outcome for gout flares: where do we stand today? Gout Urate Cryst. Depos. Dis. 2, 70–76 (2024). - DOI
    1. Pascart, T. & Lioté, F. Gout: state of the art after a decade of developments. Rheumatology 58, 27–44 (2019). - PubMed

LinkOut - more resources